Merck reported Phase 3 results for Enlicitide, an oral, once-daily PCSK9 inhibitor, showing LDL cholesterol reductions up to 60% and that two-thirds of treated patients halved their LDL levels. The 2,900-patient placebo-controlled trial tested Enlicitide in patients on statins who remained at high cardiovascular risk. The data fulfill Merck’s long-term objective to match injectable PCSK9 monoclonal antibodies’ potency with an oral therapy. Trial enrollment included patients with prior heart attack, stroke, or peripheral artery disease as well as those with major risk factors such as obesity and diabetes. An oral PCSK9 option could reshape lipid-management prescribing and access dynamics by offering a non-injectable path to deep LDL lowering, but payers and clinicians will evaluate durability, safety and real-world adherence in follow-up studies.